Nanotechnology Now - Press Release: Lumera Corporation Announces $2.2 million Air Force Contract

Home > Press > Lumera Corporation Announces $2.2 million Air Force Contract

Abstract:
Lumera Corporation (NASDAQ:LMRA), a leader in the field of photonic communications, announced today that it had received a contract from the US Air Force Research Laboratory valued at approximately $2.2 million to fabricate low driving voltage, reliable electro-optic modulators using Lumera's high-performance organic polymers.

Lumera Corporation Announces $2.2 million Air Force Contract

BOTHELL, WA | Posted on March 20th, 2008

"Current concepts of phased array radar and high-performance satellite systems require high-bandwidth electro-optic modulators with low driving voltages and wide bandwidths," said Dr. Raluca Dinu, Vice President, Electro-Optic Business Unit. "Lumera's EO devices have made significant strides in reaching these very aggressive goals, and we look forward to meeting the Air Force's requirements over the course of the contract."

RF photonics, in which optical components and optical fiber are used to process and distribute high-speed electrical signals, may provide the high bandwidth, reduced weight and size, and the immunity to electromagnetic interference that are crucial for future high-performance satellites and phased array radars. Due to the intrinsic dielectric properties of organic polymers and the great diversity of techniques used to design materials at the molecular level, electro-optic polymer devices are well suited to meeting these challenges.

####

About Lumera Corporation
Lumera is a leader in photonic communications. The company designs electro-optic components based on proprietary polymer compounds for the telecommunications and computing industries. Through its wholly owned subsidiary, Plexera Bioscience LLC, the company is also in the bioscience industry. Plexera is focused on providing the life sciences market with tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

For more information, please click here

Contacts:
Investor Relations:
Lumera Corporation
Hélčne F. Jaillet, Ph.D.
425-398-6546
or
Media:
The Summit Group Communications
Todd Wolfenbarger
801-595-1155
Cell: 801-244-9600

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: